NRIX Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
$36.33 +3.84 (11.82%)
As of 03/05/2021 15:59:55 EST IEX book CBOE book
Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Small cap
Health Care
Biotechnology
USA
USA
07/24/2020
38,907,223
440,667
$1,421,280,856
0.00%
SEC Edgar Online
10-Q
10-K
67080M103
US67080M1036
BMVLGP2
Common stocks
Small cap
Health Care
Biotechnology
USA
USA
07/24/2020
38,907,223
440,667
$1,421,280,856
0.00%
SEC Edgar Online
10-Q
10-K
67080M103
US67080M1036
BMVLGP2
Valuation (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-32.87
4.90
79.76
-14.90%
-242.66%
4.90
79.76
-14.90%
-242.66%